Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574053 · ClinicalTrials.gov registry record
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
A clinical trial of Huntington's Disease, sponsored by CHDI Foundation.
- Recruiting
- Registry status
- 35,000
- Enrollment target
- 20
- Study locations
NCT01574053: Recruiting study of Huntington's Disease, sponsored by CHDI Foundation.
NCT01574053 is a study of Huntington's Disease that is actively recruiting participants, run by CHDI Foundation. The registered enrollment target is 35,000 participants, above the 419-participant average among 8 other Huntington's Disease trials with a reported enrollment target (8253% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01574053, a study of Huntington's Disease, is actively recruiting participants, sponsored by CHDI Foundation.
- RECRUITING
- Registry status
- 35,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
Primary Outcome
The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. UHDRS 99 Motor, UHDRS Diagnostic Confidence Level.
Conditions Studied
Study Locations (20)
California
- University of California - Irvine Medical Center - Irvine
- Loma Linda Medical Center - Loma Linda
- University of California - Los Angeles - Los Angeles
- University of California - Davis - Sacramento
- University of California - San Diego - San Diego
- University of California - San Francisco - San Francisco
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
- Rush University Medical Center - Chicago
- University of Illinois College of Medicine at Rockford - Rockford
Florida
- University of Florida Board of Trustees - Gainesville
- University of Miami - Miami
- University of South Florida, HDSA Center of Excellence at USF - Tampa
Georgia
- Emory University, Wesley Woods Health Center - Atlanta
- Georgia Health Sciences University - Augusta
Alabama
- University of Alabama - Birmingham
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Colorado
- Cenexel Rocky Mountain Clinical Research, LLC - Englewood
Connecticut
- University of Connecticut - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,000 participants |
| Start Date | 2012-07 |
| Est. Completion | 2062-01 |
What NCT01574053 shows while recruiting
NCT01574053 is an observational study that tracks outcomes without assigning an intervention. Its 35,000 participants enrollment target places it among the larger protocols in the corpus, above the 419-participant average among 8 other Huntington's Disease trials with a reported enrollment target (8253% higher).
The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01574053 names 20 study sites across 9 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT01574053 about?
NCT01574053 is a clinical study titled "Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort". Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into...
What is the current status of trial NCT01574053?
This trial is currently recruiting. The enrollment target is 35,000 participants. The study started on 2012-07. Estimated completion is 2062-01.
What conditions does trial NCT01574053 study?
This clinical trial studies the following conditions: Huntington's Disease.
Who is sponsoring clinical trial NCT01574053?
This trial is sponsored by CHDI Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01574053 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01574053's enrollment target sits among peer trials
35,000 1st of 8 higher than 8 of 8 other Huntington's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
RECRUITING
-
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
RECRUITING
-
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
COMPLETED · Phase 1
-
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
COMPLETED · Phase 2
-
FuRST 2.0 Cognitive Pre-Testing
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia